TY - JOUR T1 - <span hwp:id="article-title-1" class="article-title">Review: intranasal mupirocin ointment reduces <em>Staphylococcus aureus</em> infections in nasal carriers</span><span hwp:id="article-title-2" class="sub-article-title">Review: intranasal mupirocin ointment reduces <em>Staphylococcus aureus</em> infections in nasal carriers</span> JF - Evidence Based Medicine JO - Evid Based Med SP - 110 LP - 110 DO - 10.1136/ebm.14.4.110 VL - 14 IS - 4 AU - Kent Crossley Y1 - 2009/08/01 UR - http://ebm.bmj.com/content/14/4/110.abstract N2 - Does mupirocin nasal ointment reduce Staphylococcus aureus infections in patients who are nasal carriers of S aureus?Included studies compared intranasal mupirocin ointment with placebo, no treatment, or an alternative topical treatment in hospital inpatients or outpatients who were nasal carriers of microbiologically confirmed S aureus. Outcomes included S aureus infection, infection caused by other micro-organisms, and mortality.Cochrane Wounds Group Specialised Register, CENTRAL, Medline, CINAHL, EMBASE/Excerpta Medica (all to May 2008); System for Information on Grey Literature; Index to Theses (ASLIB Index); mRCT; ClinicalTrials.gov; abstracts from major scientific meetings (1995–2007); and reference lists were searched for published and unpublished randomised controlled trials (RCTs). Researchers, the manufacturer of mupirocin, and … ER -